| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |